Home
Search

Letters, Testimony & Comments

BIO submits letters, testimony, and comments to government and regulatory bodies throughout the United States and around the world.

Featured Letters, Testimony, & Comments
Testimony of John F. Crowley President and CEO,…
Chairman Griffith, Chairman Guthrie, Ranking Member DeGette, Ranking Member Pallone, and distinguished members of the subcommittee, thank you for the opportunity to appear before you today on behalf of the Biotechnology Innovation Organization (BIO)…
Learn more
CSBA Letter to Congressional Leaders on PBM, PPRV…
Dear Congressional Leaders:On behalf of the Council of State Bioscience Associations (CSBA)—a national coalition of independent, state and territory-based organizations representing the full breadth of America’s biotechnology ecosystem—we write to…
Learn more
BIO's Comments on Advisory Committee on…
Re: Docket No. CDC-2025-0783; Advisory Committee on Immunization Practices (ACIP) MeetingDear Dr. Zadeh and Members of the ACIP:The Biotechnology Innovation Organization (BIO) appreciates the opportunity to provide comments to the Advisory Committee…
Learn more
All Letters, Testimony & Comments
  • Show All
Search
Results
BIO Comments on FDA Natural Food Labeling
May 11, 2016
The Biotechnology Innovation Organization (BIO) is pleased to submit these comments to FDA in response to FDA’s request for information on the use of the term “natural” on food labeling (docket no. FDA-2014-N-1207). BIO is the world's largest…
BIO Submits Comments Re: Medicare Program; Part B Drug Payment Model [CMS-1670-P]
May 9, 2016
The Biotechnology Innovation Organization appreciates this opportunity to submit comments on the Centers for Medicare and Medicaid Services’ proposed rule entitled Medicare Program; Part B Drug Payment Model...
Follow-Up on BIO’s Comments in Response to the ICER Value Framework
May 4, 2016
The Biotechnology Innovation Organization (BIO) would like to take the opportunity to follow-up and expand on the feedback we originally submitted to the Institute for Clinical and Economic Review (ICER) in October 2015 on the ICER Value Framework …
BIO letter in support of H.R. 5418
March 10, 2016
To establish a pilot program for educating district court judges on patent related issues.
Cures Acceleration Network: Legislative Text
March 10, 2016
The Cures Acceleration Network, passed in the recently enacted healthcare reform bill, will provide funding to public and private entities to bridge the gap between basic research and cures for patients.
Small Business Early Stage Investment Program: Legislative Text
March 10, 2016
The Small Business Early Stage Investment Program would provide matching funds for investment companies who invest in small, high tech companies, including biotech firm.
BIO’s comments to the USDA on the biomass crop assistance program enacted by the 2008 Farm Bill
March 10, 2016
Comments are regarding conservation and stewardship requirements, matching payments, establishment costs and annual payments, disclosure of competitively sensitive information, invasiveness determination and review, consistency with existing FSA…
Presentation: "Global Health Challenges: How Industry is Addressing Global Health", presented at the University of Virginia in June 2008
March 10, 2016
Global Health Challenges: How Industry is Addressing Global Health
Diran Makinde, Network Director, NEPAD Biosciences, West Africa Biosciences Network (WABNet), Senegal
March 10, 2016
Government's role in developing solutions for diseases that disproportionately affect developing countries
Mark Rohrbaugh, Director, Office of Technology Transfer, National Institutes of Health (NIH)
March 10, 2016
Mark Rohrbaugh, Director, Office of Technology Transfer, National Institutes of Health (NIH), US Department of Health & Human Services, USA